Skip to main content
SP5007,798.99+0.65%DOW53,839.99+0.13%NASDAQ26,803.03+0.81%BTC$63,430.00+0.04%ETH$1,885.21+0.41%GOLD$4,414.30-0.14%OIL$81.35+0.12%
Smart Investors Daily
Sign InSign Up Free
PL

NASDAQ · PLUR

Pluri Inc.

Healthcare · Biotechnology

$1.63

Up+$0.04 (+2.24%)

Updated Aug 13, 2026, 11:53 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
22.63M
P/E ratio
-0.84
Dividend yield
0.00%
52-week range
$1.45 – $3.89
Volume
14.61K
Avg. volume
29.37K

Price performance

PLUR price history

1M range · 21 trading sessions · Daily adjusted prices

PLUR closed at $1.63 after 21 trading sessions, down 7.14% for the selected period.

Last close
$1.63
Period change
-7.14%
Period low
$1.55
Period high
$1.95
Daily close
View OHLC price history
PLUR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 12, 2026$1.75$1.75$1.625$1.62514.61K
Aug 11, 2026$1.82$1.82$1.66$1.7510.96K
Aug 10, 2026$1.82$1.8466$1.7717$1.8414.94K
Aug 7, 2026$1.82$1.82$1.82$1.822.44K
Aug 6, 2026$1.75$1.8321$1.75$1.815.14K
Aug 5, 2026$1.70$1.859$1.67$1.7461.2K
Aug 4, 2026$1.625$1.625$1.54$1.5635.68K
Aug 3, 2026$1.58$1.58$1.55$1.5753K
Jul 31, 2026$1.61$1.64$1.45$1.5536K
Jul 30, 2026$1.59$1.6375$1.55$1.5611.49K
Jul 29, 2026$1.67$1.67$1.55$1.5810.41K
Jul 28, 2026$1.65$1.7299$1.64$1.688.66K
Jul 27, 2026$1.79$1.79$1.60$1.6428.41K
Jul 24, 2026$1.74$1.78$1.66$1.789.36K
Jul 23, 2026$1.8304$1.8728$1.75$1.79512.07K
Jul 22, 2026$1.95$1.95$1.84$1.8527.93K
Jul 21, 2026$1.84$1.95$1.84$1.9530.51K
Jul 20, 2026$1.97$1.97$1.71$1.8253.05K
Jul 17, 2026$1.85$2.0093$1.81$1.8637.33K
Jul 16, 2026$1.75$1.9457$1.73$1.8077.59K
Jul 15, 2026$1.68$1.75$1.67$1.7513.72K

Latest PLUR news

The latest Smart Investors Daily articles mentioning PLUR.

Stock researchCompany · Overview

PLUR research

Overview

Company profile and research snapshot.

Company profile

Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$12.00
Implied upside
—
Analysts
—
PLUR recent ratings
DateFirmRatingTarget
Jun 2, 2025Alliance Global PartnersBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jul 28, 2026

Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK

UK regulatory registration supports commercial launch of regenerative aesthetics portfolio in a market with an estimated size of ~$900 million annually, and strengthens the foundation for broader international expansion HAIFA, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announc

Yahoo · Jul 14, 2026

Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%

Through a series of investments over the past year, including an additional investment made in June 2026, Weinstein has built an ownership position of more than 30% as Pluri advances its longevity and U.S. commercialization strategyHAIFA, Israel, July 14, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today provided an update on the cumulative investment and ownership position of

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By